New pill targets Hard-to-Treat cancer mutation in early trial
Disease control
Recruiting now
This study tests a new drug called TSN1611 in people with advanced solid tumors that have a specific genetic change called KRAS G12D. The trial has two parts: first, finding the safest dose, and second, seeing if the drug shrinks tumors. About 440 adults will take part, and the d…
Phase: PHASE1, PHASE2 • Sponsor: Tyligand Pharmaceuticals (Suzhou) Limited • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC